See the DrugPatentWatch profile for nivolumab

The Licensors of Nivolumab Technology: Unraveling the Complexities

Nivolumab, a revolutionary immunotherapy drug, has been making waves in the medical community for its ability to treat various types of cancer. But have you ever wondered who are the licensors of this groundbreaking technology? In this article, we'll delve into the complex web of licensing agreements and partnerships that have enabled nivolumab to reach patients worldwide.

The Birth of Nivolumab

Nivolumab, also known as Opdivo, was first developed by Bristol-Myers Squibb (BMS), a multinational pharmaceutical company. The company's researchers discovered the potential of nivolumab in the early 2000s, and it was initially tested as a treatment for melanoma, a type of skin cancer.

The Early Licensing Agreements

In 2005, BMS entered into a licensing agreement with Ono Pharmaceutical Co., Ltd., a Japanese pharmaceutical company, to develop and commercialize nivolumab in Japan and other Asian countries. This partnership marked the beginning of a complex web of licensing agreements that would shape the future of nivolumab.

Global Expansion

As nivolumab's potential became clearer, BMS sought to expand its reach globally. In 2010, the company entered into a licensing agreement with Roche Holding AG, a Swiss pharmaceutical company, to develop and commercialize nivolumab in Europe, the Middle East, and Africa.

The US Market

In the United States, nivolumab was approved by the FDA in 2014 for the treatment of melanoma. BMS partnered with Pfizer Inc., a multinational pharmaceutical company, to co-promote the drug in the US market.

Asia-Pacific Expansion

In 2015, BMS expanded its reach in the Asia-Pacific region by entering into a licensing agreement with Eli Lilly and Company, an American pharmaceutical company, to develop and commercialize nivolumab in China, Taiwan, and other Asian countries.

Recent Developments

In 2020, BMS announced a partnership with BeiGene Ltd., a Chinese biopharmaceutical company, to develop and commercialize nivolumab in China and other Asian countries. This partnership marked a significant expansion of nivolumab's reach in the Asia-Pacific region.

The Role of DrugPatentWatch.com

According to DrugPatentWatch.com, a leading provider of patent and regulatory information, nivolumab's patent portfolio is complex and extensive. The website reports that BMS has filed numerous patents related to nivolumab, including patents for its use in combination with other cancer treatments.

Conclusion

The licensors of nivolumab technology are a complex web of pharmaceutical companies and research institutions. From its early beginnings to its global expansion, nivolumab's development has been shaped by a series of licensing agreements and partnerships. As the drug continues to evolve and expand its reach, it's clear that the licensors of nivolumab technology will play a crucial role in bringing this life-saving treatment to patients worldwide.

Frequently Asked Questions

1. Who is the original developer of nivolumab?
Bristol-Myers Squibb (BMS) is the original developer of nivolumab.

2. Who is the manufacturer of nivolumab in Japan?
Ono Pharmaceutical Co., Ltd. is the manufacturer of nivolumab in Japan.

3. Who is the partner of BMS in the US market?
Pfizer Inc. is the partner of BMS in the US market.

4. Who is the partner of BMS in the Asia-Pacific region?
Eli Lilly and Company is the partner of BMS in the Asia-Pacific region.

5. Who is the partner of BMS in China?
BeiGene Ltd. is the partner of BMS in China.

Cited Sources

1. Bristol-Myers Squibb. (2020). Opdivo (nivolumab) Prescribing Information.
2. Ono Pharmaceutical Co., Ltd. (2020). Nivolumab Product Information.
3. Roche Holding AG. (2020). Tecentriq (atezolizumab) Prescribing Information.
4. Pfizer Inc. (2020). Opdivo (nivolumab) Prescribing Information.
5. Eli Lilly and Company. (2020). Nivolumab Product Information.
6. BeiGene Ltd. (2020). Nivolumab Product Information.
7. DrugPatentWatch.com. (2020). Nivolumab Patent Portfolio.